Basis of anti-infective therapy: pharmacokinetic-pharmacodynamic criteria and methodology for dual dosage individualisation
- PMID: 10554046
- DOI: 10.2165/00003088-199937040-00002
Basis of anti-infective therapy: pharmacokinetic-pharmacodynamic criteria and methodology for dual dosage individualisation
Abstract
Antimicrobial therapy should be designed on the basis of microbiological, as well as pharmacokinetic, criteria; microbiological parameters provide information about the susceptibility of the pathogen responsible for the infectious process while pharmacokinetic parameters give information about the potential ability of the drug in question to reach and remain at the sites of infection in the body. Microbiological parameters such as the minimum inhibitory concentration, minimum bactericidal concentration, bacterial titre, bactericidal rate and 'post-antibiotic effect' (PAE) must be considered. Among the pharmacokinetic parameters, the maximum serum concentration at steady state (CmaxSS), area under the concentration-time curve (AUC) and length of time that the serum concentrations exceed a particular value are the most useful in this context. Different relationships between these parameters, known as efficacy indices, have been established to predict the potential efficacy of antibacterial therapy. Antimicrobial dosage individualisation should be based on the optimisation of the efficacy index that best correlates with patient response. It seems appropriate to establish the degree of correlation among the different efficacy indices and clinical response observed in patients by means of a correlation analysis. This type of analysis can be either retrospective or prospective and may be based on linear or maximum response models. Simulation of the plasma concentration curves obtained with the particular regimen administered offers a methodology which is easy to apply and provides the pharmacokinetic information necessary to calculate the different efficacy indices. Information about the susceptibility of the pathogen to the antibacterial in question and about the response to the treatment used is also necessary for the correlation analysis. This type of analysis determines which of the indices is best correlated with efficacy and, hence, is the index to be optimised when attempting to individualise antibacterial therapy for different situations.
Similar articles
-
The economic potential of dual individualisation methodologies.Pharmacoeconomics. 1996 Dec;10(6):539-45. doi: 10.2165/00019053-199610060-00002. Pharmacoeconomics. 1996. PMID: 10164056 Review.
-
Selecting antibacterials for outpatient parenteral antimicrobial therapy : pharmacokinetic-pharmacodynamic considerations.Clin Pharmacokinet. 2003;42(9):793-817. doi: 10.2165/00003088-200342090-00002. Clin Pharmacokinet. 2003. PMID: 12882587 Review.
-
The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents.Clin Pharmacokinet. 1995 Feb;28(2):143-60. doi: 10.2165/00003088-199528020-00005. Clin Pharmacokinet. 1995. PMID: 7736689 Review.
-
A retrospective analysis of pharmacokinetic/pharmacodynamic indices as indicators of the clinical efficacy of ciprofloxacin.J Antimicrob Chemother. 2000 Mar;45(3):321-8. doi: 10.1093/jac/45.3.321. J Antimicrob Chemother. 2000. PMID: 10702551
-
Selecting antibiotics based on pharmacokinetic and pharmacodynamic principles.Pharm Pract Manag Q. 1996 Jul;16(2):9-12. Pharm Pract Manag Q. 1996. PMID: 10161616
Cited by
-
Pharmacokinetic/pharmacodynamic evaluation of antimicrobial treatments of orofacial odontogenic infections.Clin Pharmacokinet. 2005;44(3):305-16. doi: 10.2165/00003088-200544030-00006. Clin Pharmacokinet. 2005. PMID: 15762771
-
Pharmacokinetic/pharmacodynamic analysis of vancomycin in ICU patients.Intensive Care Med. 2007 Feb;33(2):279-85. doi: 10.1007/s00134-006-0470-5. Epub 2006 Dec 13. Intensive Care Med. 2007. PMID: 17165021
-
A retrospective analysis of pharmacokinetic-pharmacodynamic parameters as indicators of the clinical efficacy of ceftizoxime.Clin Pharmacokinet. 2001;40(2):125-34. doi: 10.2165/00003088-200140020-00004. Clin Pharmacokinet. 2001. PMID: 11286322 Review.
-
Antimicrobial treatment of febrile neutropenia: pharmacokinetic-pharmacodynamic considerations.Clin Pharmacokinet. 2013 Oct;52(10):869-83. doi: 10.1007/s40262-013-0086-1. Clin Pharmacokinet. 2013. PMID: 23807657 Review.
-
Once-daily administration of antiretrovirals: pharmacokinetics of emerging therapies.Clin Pharmacokinet. 2003;42(14):1179-91. doi: 10.2165/00003088-200342140-00001. Clin Pharmacokinet. 2003. PMID: 14606928 Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical